Licarin A, a neolignan isolated from Nectandra oppositifolia Nees & Mart. (Lauraceae), exhibited moderate preclinical efficacy against Schistosoma mansoni infection

Autor(es)

Mengarda, Ana C. ^[1] ; Silva, Marcos P. ^[1] ; Cirino, Maria E. ^[1] ; Morais, Thiago R. ^[1] ; Conserva, Geanne A. A. ^[2] ; Lago, Joao Henrique G. ^[2] ; de Moraes, Josue ^[1]

Afiliação do(s) autor(es)

^[1] Univ Guarulhos, Nucleo Pesquisa Doencas Negligenciadas, Praca Tereza Cristina 88, BR-07023070 Guarulhos, SP - Brazil

^[2] Univ Fed ABC, Ctr Ciencias Nat & Humanas, Ave Estados 5001, BR-09210180 Santo Andre, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Phytotherapy Research; v. 35, n. 9, p. 5154-5162, SEP 2021.
• Citações Web of Science: 2

Resumo

Schistosomiasis is a widespread human parasitic disease currently affecting over 200 million people, particularly in poor communities. Chemotherapy for schistosomiasis relies exclusively on praziquantel (PZQ). Previous studies have shown that licarin A (LIC-A), a dihydrobenzofuran neolignan, exhibited in vitro antiparasitic activity against Schistosoma mansoni adult worms. This study aimed to investigate the potential of LIC-A, isolated as main metabolite from leaves of Nectandra oppositifolia Nees \& Mart. (Lauraceae), as an antischistosomal agent orally active in schistosomiasis animal model. PZQ was used as a reference compound. As result, LIC-A showed, at a single dose of 400 mg/kg, to be able to partially cure infected mice (worm burden reductions of similar to 50%). Parasite eggs, that are responsible for a variety of pathologies and transmission of schistosomiasis, were also moderately inhibited by LIC-A (egg burden reductions of similar to 50%-60%). Furthermore, it was observed that LIC-A achieved a slight reduction of hepatomegaly and splenomegaly. Collectively, although LIC-A was partially active when administered orally, these results give support for the antiparasitic potential LIC-A as lead compound for novel antischistosomal agent. (AU)

• Processo FAPESP: 16/22488-3 - Reposicionamento de fármacos para doenças negligenciadas: identificação de novos agentes anti-helmínticos
• Beneficiário: Josué de Moraes
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/07885-1 - Biomoléculas oriundas de espécies vegetais de áreas remanescentes da Mata Atlântica e do Cerrado para tratamento de doenças tropicais negligenciadas - aspectos químicos e farmacológicos
• Beneficiário: João Henrique Ghilardi Lago
• Modalidade de apoio: Auxílio à Pesquisa - Programa BIOTA - Regular
• Processo FAPESP: 19/25289-0 - Atividade anti-helmíntica in vitro do praziquantel e ácido mefenâmico nanocarreados
• Beneficiário: Vinícius de Castro Rodrigues
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 19/25905-2 - Avaliação pré-clínica para administração oral de formulações nanoestruturadas contendo fármacos com atividade anti-helmíntica
• Beneficiário: Ana Carolina Araujo Mengarda
• Modalidade de apoio: Bolsas no Brasil - Doutorado